Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

Journal of Clinical Oncology

Volumn 26, Issue 19, 2008, Pages 3196-3203

  Lacy, Martha Q ^a   Alsina, Melissa ^a   Fonseca, Rafael ^a   Paccagnella, M Luisa ^a   Melvin, Carrie L ^a   Yin, Donghua ^a   Sharma, Amarnath ^a   Sarano, M Enriquez ^a   Pollak, Michael ^a   Jagannath, Sundar ^a   Richardson, Paul ^a   Gualberto, Antonio ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CP 751871; DEXAMETHASONE; INSULIN; MONOCLONAL ANTIBODY; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BIOACCUMULATION; CANCER PATIENT; CANCER RELAPSE; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; GRANULOCYTE; HUMAN; HYPERGLYCEMIA; INFORMED CONSENT; LEG CRAMP; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; DOSE RESPONSE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SIROLIMUS; TREATMENT OUTCOME;

EID: 49249125421     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.9319     Document Type: Article

References (51)

1. Bataille R, Robillard N, Avet-Loiseau H, et al: CD221 (IGF-IR) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 90:706-707, 2005
2. Chng WJ, Gualberto A, Fonseca R: IGF-IR is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia 20:174-176, 2006
3. Standal T, Borset M, Lenhoff S, et al: Serum insulin-like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 100:3925-3929, 2002
4. Tucci A, Bonadonna S, Cattaneo C, et al: Transformation of a MGUS to overt multiple myeloma: The possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1). Leuk Lymphoma 44:543-545, 2003
5. Freund GG, Kulas DT, Way BA, et al: Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res 54:3179-3185, 1994
6. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221-230, 2004
7. Georgii-Hemming P, Wiklund HJ, Ljunggren O, et al: Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 88:2250-2258, 1996
8. Li W, Hyun T, Heller M, et al: Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth. Cancer Res 60:3909-3915, 2000
9. Freund GG, Kulas DT, Mooney RA: Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 151:1811-1820, 1993
10. Jelinek DF, Witzig TE, Arendt BK: A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 159:487-496, 1997
11. Georgii-Hemming P, Stromberg T, Janson ET, et al: The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood 93:1724-1731, 1999
12. Descamps G, Pellat-Deceunynck C, Szpak Y, et al: The magnitude of Akt/phosphatidylinositol 3′-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol 173:4953-4959, 2004
13. Frostad S, Bjerknes R, Hervig T, et al: Malignancy: Insulin-like growth factor-1 (IGF-1) is a costimulator of the expansion of lineage committed cells derived from peripheral blood mobilized CD34+ cells in multiple myeloma patients. Hematology 4:217-229, 1999
14. Xu F, Gardner A, Tu Y, et al: Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol 97:429-440, 1997
15. Ferlin M, Noraz N, Hertogh C, et al: Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6- independent transduction pathway. Br J Haematol 111:626-634, 2000
16. Ge NL, Rudikoff S: Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 96:2856-2861, 2000
17. Asosingh K, Gunthert U, Bakkus MH, et al: In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res 60:3096-3104, 2000
18. Vanderkerken K, Asosingh K, Braet F, et al: Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 93:235-241, 1999
19. Suzuki A, Iida S, Kato-Uranishi M, et al: ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 24:6936-6944, 2005
20. Nishiura T, Karasuno T, Yoshida H, et al: Functional role of cation-independent mannose 6-phosphate/insulin-like growth factor II receptor in cell adhesion and proliferation of a human myeloma cell line OPM-2. Blood 88:3546-3554, 1996
21. Asosingh K, De Raeve H, Croucher P, et al: In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells. Exp Hematol 29:77-84, 2001
22. Arteaga CL, Kitten LJ, Coronado EB, et al: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418-1423, 1989
23. Araki K, Sangai T, Miyamoto S, et al: Inhibition of bone-derived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse. Int J Cancer 118:2602-2608, 2006
24. Wu KD, Zhou L, Burtrum D, et al: Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56:343-357, 2007
25. Menu E, Jernberg-Wiklund H, Stromberg T, et al: Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: An in vitro and in vivo study in the 5T33MM mouse model. Blood 107:655-660, 2006
26. Cohen BD, Baker DA, Soderstrom C, et al: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073, 2005
27. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
28. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
29. Jagannath S, Richardson PG, Barlogie B, et al: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91:929-934, 2006
30. Haluska P, Shaw HM, Batzel GN, et al: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-5840, 2007
31. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
32. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
33. Yan H, Frost P, Shi Y, et al: Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 66:2305-2313, 2006
34. Stromberg T, Dimberg A, Hammarberg A, et al: Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103:3138-3147, 2004
35. Shi Y, Yan H, Frost P, et al: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/ phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4:1533-1540, 2005
36. O'Reilly KE, Rojo F, She QB, et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006
37. Gualberto A, Alsina M, Lacy MQ, et al: Inhibition of the insulin like growth factor 1 receptor by a specific monoclonal antibody in multiple myeloma. J Clin Oncol 23:203s, 2005 (abstr 3048)
38. Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317:137-140, 1987
39. Moses AC, Young SC, Morrow LA, et al: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91-100, 1996
40. Clemmons DR: Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 6:620-625, 2006
41. Pennisi P, Gavrilova O, Setser-Portas J, et al: Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619-2630, 2006
42. Kurtz A, Jelkmann W, Bauer C: A new candidate for the regulation of erythropoiesis: Insulin-like growth factor I. FEBS Lett 149:105-108, 1982
43. Aron DC: Insulin-like growth factor I and erythropoiesis. Biofactors 3:211-216, 1992
44. El Yafi F, Winkler R, Delvenne P, et al: Altered expression of type I insulin-like growth factor receptor in Crohn's disease. Clin Exp Immunol 139:526-533, 2005
45. Clemmons DR, Chihara K, Freda PU, et al: Optimizing control of acromegaly: Integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 88:4759-4767, 2003
46. Mager DE: Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1-10, 2006
47. Burtrum D, Zhu Z, Lu D, et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912-8921, 2003
48. Maloney EK, McLaughlin JL, Dagdigian NE, et al: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073-5083, 2003
49. Abuzzahab MJ, Schneider A, Goddard A, et al: Intrauterine Growth Retardation (IUGR) Study Group: IGF-I receptor mutations resulting in intra-uterine and postnatal growth retardation. N Engl J Med 349:2211-2222, 2003
50. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
51. Ogawa M, Nishiura T, Oritani K, et al: Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 60:4262-4269, 2000